Catalog No.S7377

For research use only.

Aprotinin is a small protein serine protease inhibitor (Kd=0.06 pM for bovine β-trypsin), used to reduce perioperative blood loss and transfusion.

CAS No. 9087-70-1

Selleck's Aprotinin has been cited by 2 Publications

Purity & Quality Control

Choose Selective Serine Protease Inhibitors

Biological Activity

Description Aprotinin is a small protein serine protease inhibitor (Kd=0.06 pM for bovine β-trypsin), used to reduce perioperative blood loss and transfusion.
Thrombin [1]
(Cell-free assay)
Trypsin [1]
(Cell-free assay)
kallikrein [1]
(Cell-free assay)
chymotrypsin [1]
(Cell-free assay)
trypsinogen [1]
(Cell-free assay)
0.06 pM(Kd) 0.8 nM(Kd) 9.5 nM(Kd) 2 μM(Kd)
In vitro

Aprotinin is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. In cell biology, aprotinin is used as an enzyme inhibitor to prevent protein degradation during lysis or homogenization of cells and tissues. In the presence of aprotinin, the fibrinolytic activity is inhibited concentration dependently and the coagulation time is prolonged. Aprotinin is an effective inhibitor of the contact (intrinsic) coagulation pathway in vitro[2].

In vivo Aprotinin inhibits clot lysis in vitro as well as rat-tail bleeding time in vivo and prolongs coagulation time in human plasma. In a rat arteriovenous shunt model, aprotinin reduces thrombus weight [2].

Protocol (from reference)

Cell Research:


  • Cell lines: mouse G8-1 and C2C12 skeletal muscle myoblasts
  • Concentrations: 2 TIU/ml
  • Incubation Time: 12hrs
  • Method:

    Mouse G8-1 myoblasts are plated DMEM + 20% FBS (maintenance medium), in which they remain undifferentiated. When cells reach approximately 40-50% confluence, different protease inhibitors are added to the culture media and cells are incubated overnight. Cells are then switched to differentiation-promoting media (DMEM + 10% horse serum ± protease inhibitor) and incubated for 7 days.

Animal Research:


  • Animal Models: Male Wistar rats
  • Dosages: 1.5 mg/kg and 3 mg/kg/h, 3 mg/kg and 6 mg/kg/h up to 5 mg/kg and 10 mg/kg/h
  • Administration: bolus injection followed by a maintenance infusion(i.p.)

Solubility (25°C)

In vitro

Water 100 mg/mL
(15.35 mM)

Chemical Information

Molecular Weight 6511.51


CAS No. 9087-70-1
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01554956 Completed Biological: Human Plasminogen Ligneous Conjunctivitis Kedrion S.p.A. May 22 2013 Phase 2|Phase 3
NCT00481806 Unknown status -- Coronary Artery Bypass|Thrombosis University of Arizona|University of Maryland Baltimore County February 2007 --
NCT00354900 Terminated Drug: Aprotinin Metastatic Breast Cancer Dartmouth-Hitchcock Medical Center July 2006 Phase 1
NCT00131040 Completed Drug: Aprotinin Ischemic Heart Disease|Angina Pectoris Imperial College London|British Heart Foundation January 2003 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aprotinin | Aprotinin supplier | purchase Aprotinin | Aprotinin cost | Aprotinin manufacturer | order Aprotinin | Aprotinin distributor